List of Antibodies Companies in Taiwan - 11

Abnova is the first biotech company successfully integrated the IT-style management and industrial-scale antibody manufacturing. Our goal is to have at least one antibody to every human expressed gene in human genome. In Phase I of our business plans, we vastly expand the scope and availability of antibody reagents for the research market by taking a genome-wide approach to the high throughput production of human protein and antibody. There products are marketed through a combination of E-commerce based direct sales and a multi-tiered, sales network of over 49 distributors around the world. Starting from Year 2009 to 2013, in Phase II of the business plans, we have diversified into the systems arena focusing on antibody pairs, ELISA kits and instrumentation for rare cell isolation. In Phase III, we focus on in vitro diagnostics development concentrating on non-invasive, liquid biopsies of circulating tumor cells, ctDNA, and exosomes for precision medicine. Now in Phase IV (Year 2017 and later), we have focused on drug development specializing on immunotherapy. The value-added business has set the path of company's future growth and provided opportunity for Abnova to contribute to the biotech industry at large. We welcome researchers, biotech, and pharmaceutical companies to work with us and succeed together!

Elixiron Immunotherapeutics is driven by a multi-cultural, international team in Shanghai, Taipei, the USA (San Francisco) and Switzerland (Lausanne) with a shared vision to build a global company that brings next-generation immunotherapies to patients in need. This vision drives our mission to target rare and immunological diseases as well as cancer for indications that could substantially benefit from advances in immunotherapy approaches. We employ advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics derived from a proprietary human antibody domain phage display library and a single human B cell antibody cloning platform to develop innovative therapies. Our two lead pipeline candidates are in phase 1 clinical trials. EI-1071, a small molecule inhibitor of CSF-1R kinase activity, is being explored as a potential therapy for Alzheimer's disease as well as tenosynovial giant cell tumors, and a monoclonal antibody, EI-001 is being developed for the treatment of vitiligo and other immunological disorders.

GlycoNex Inc. was founded in 2001, in alliance with The Biomembrane Institute (TBI) from Washington University and Dr. Sen-Itiroh Hakomori, a member of the National Academy of Sciences (USA). GlycoNex was the first pharmaceutical company in Taiwan to combine cancer-related glycan identification with human monoclonal antibody development. GlycoNex Inc. possesses a complete and detailed technological platform for anti-glycan antibody development, including multiple acquired licensed patents. Our pipeline consists of new drug development in parallel with biosimilars. Our new drugs were selected and developed through a detailed antigen/antibody characterization and cell line development. In 2009, we licensed GNX8 to Otsuka Pharmaceutical Co., Ltd. In 2019, our first-in-class new drug GNX102 received FDA IND approval. In 2020, we initiated our Clinical Trial Phase I dose-escalation study for GNX102 and received TFDA IND approval. In parallel, our biosimilar products Denosumab and Aflibercept have completed different volumes of pilot studies and data ready for review. We aim to look for opportunities of out-licensing our products or co-develop in cooperation.

HuniLife Biotechnology, Inc. is a Taiwan-based biopharmaceutical company founded in 2013. HuniLife strives to develop efficacious new drugs and treatments to improve human health and well-being. The company focuses on drug pipelines, patents, clinical trials, and investment in the biopharmaceutical industry.

Immunwork, Inc. is a privately held biotech company focusing on the research, development, and commercialization of novel drugs to fulfill unmet medical needs. Our drugs are created based on our proprietary technology platform for treating multiple types of cancer, diabetes, obesity, non-alcoholic steatohepatitis (NASH), pathological blood clots, and other selected severe clinical conditions. Our unique platform allows us to design and generate novel “T-E” drug molecules, which contain targeting (T) and effector (E) moieties. These designs would help to improve the efficacy and limit toxicity. The majority of our T-E drugs are based on “multi-arm linkers” and various “drug bundles”. These drug candidates include antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), ultra-long-acting therapeutic peptides, and drugs in other modalities. Six of the drug candidates have been selected and progressed into the pre-clinical development stage. Meanwhile, we are looking forward to applying the multi-arm linker platform for designing additional novel drug candidates.

OBI Pharma, Inc. is a Taiwan based bio-pharma company founded in 2002. Our mission is to improve health and the quality of life through innovative cancer therapeutics. We seek to develop and license novel therapeutic agents for unmet medical needs against cancer by targeting the Globo Series antigens (Globo H, SSEA-4), the AKR1C3 enzyme, and other promising targets. Our leading compound is Adagloxad simolenin, a late-stage novel active immuno-oncology (IO) Globo Series-based therapeutic vaccine for the treatment of epithelial cancers, such as breast, ovarian, lung, prostate, colon, gastric, and pancreatic cancer. OBI has a full spectrum of Globo Series IO pipeline, which includes both active (vaccine) and passive (monoclonal antibody & antibody drug conjugate) therapeutics. Development of OBI-888 (Globo H monoclonal antibody), OBI-833 (Globo Series vaccine) for epithelial cancers, OBI-999 (Globo H antibody drug conjugate), OBI-898 (SSEA-4 monoclonal antibody), and OBI-866 (SSEA-4 vaccine) for multiple cancers are also underway. In addition, development of OBI-3424, a novel First-in-Class compound targeting both solid and liquid that express the Aldo Keto Reductase 1C3 enzyme, further enriches the company’s pipeline profile. OBI Pharma, Inc. is publicly listed on the Taipei Exchange (TPEx: 4174); wholly-owned subsidiaries are present in the United States and China. The company is led by management team with a track record of success in new drug development and commercialization.

Oneness Biotech is dedicated to fulfilling unmet medical needs by developing new drugs focused on chronic disorders in dermatology and immunology

Noticing that antibody drugs can effectively cure diseases but at the same time cause severe adverse effects because of on-target toxicity, PrecisemAb, just like our name "Precise + mAb", is committed to creating the safest antibody therapy for patients. Our Universal Antibody Lock technology could "inactivate" antibody's binding ability by giving it a "Lock" on the biding site. The binding ability of antibody is limited in healthy tissues unless antibody encounters disease-associated protease in the diseased site. The cleaved Lock-antibody is designed to be specifically activated and neutralize the target antigen to inhibit the disease progression. Therefore, our antibody lock technology can effectively enhance antibody drugs’ selectivity in disease area and consequently reduce side effects caused by on-target toxicity. We at PrecisemAb deeply believe in scientific thinking and cultural diversity since innovations always come from diversity, and scientific mind can transform creativities into practical solutions. This belief is not only applied to how we work internally but also how we collaborate with external partners and how we contribute back to our society.

TaiMed Biologics, founded in 2007, is a leading biopharmaceutical developer and manufacturer in Taiwan. We have extensive monoclonal antibodies (mAb) development and manufacturing experiences and have successfully developed and commercially launched the first and only mAb for HIV treatment in the US and Europe (Brand name: Trogarzo®). We are proud to offer Contract Development and Manufacturing Organization (CDMO) services for biopharmaceutical companies to propel your important monoclonal antibody molecules from development to market launch.

TaiRx, Inc. was founded in 2011 under the strategic alliance of Formosa Laboratories, Inc. and Efficient Pharma Management Corporate to develop a new generation of oncology molecule. In 2013, TaiRx started a series of financing and expanded the drug pipeline. In addition to cancer treatment, we also extended our reach to the therapy of other major diseases. TaiRx has a rich product pipeline and many of our products are moving rapidly into various clinical stages to ensure the safety and efficacy of the drug products. TaiRx continues to search for novel cures for serious diseases and deliver them to the medical community to help those in need. With Taiwan as our home base, we have successfully recruited many experts and consultants in new drug development worldwide. With our extensive experience and expertise in drug development, we can rapidly add value to our product line by moving the progress of our drug products forward. We are committed to our pursuit of high quality and scientific excellence, and establishing global collaboration and partnering. Our goal is to become a global drug development company and deliver new therapeutic hopes for the severe diseases.

United BioPharma (UBP) was established in September 2013 as a spinoff company from UBI which was founded in 1985 in the USA. UBP focuses on developing, manufacturing, and marketing integrated therapeutic mAb products and related technologies. In addition, UBP also provides fully integrated and high-quality CDMO services. We commit to meeting our client's needs. Among +250 employees, 50% are in R&D and 65% have a master’s degree or higher. Global facilities of UBP include clinical development, R&D, manufacturing centers in Taiwan and China, as well as business centers in the USA and Taiwan.